Enzimas hepáticas

1. Aragon G, Younossi ZM. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med 2010; 77(3):195–204. doi:10.3949/ccjm.77a.09064

2. Chalasani N, Younossi Z, Lavine JE, et al; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142(7):1592–1609.

3. Cohen JA, Kaplan MM. The SGOT/SGPT ratio—an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24(11):835–838. pmid:520102

4. Kaplan MM. Alanine aminotransferase levels: what’s normal? Ann Intern Med 2002; 137(1):49-51. pmid:12093245

5. Pratt DS, Kaplan MM. Evaluation of abnormal liver enzyme results in asymptomatic patients. N Engl J Med 2000; 342(17):1266–1271.

6. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem 2014; 29(3):269–278.

7. Weibrecht K, Dayno M, Darling C, Bird SB. Liver aminotransferases are elevated with rhabdomyolysis in the absence of signifi cant liver injury. J Med Toxicol 2010; 6(3):294–300.

8. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28(1):155–161.

9. Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis 2011; 12(1):10–16.

10. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48(3):792–798. doi:10.1002/hep.22429

11. Tahan V, Canbakan B, Balci H, et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterolgoy 2008; 55(85):1433-1438. pmid:18795706

12. McPherson S, Stewart S, Henderson E, Burt AD, Day CP. Simple non-invasive fi brosis scoring systems can reliably exclude advanced fi brosis in patients with non-alcoholic fatty liver disease. Gut 2010;59(9):1265–1269. doi:10.1136/gut.2010.216077

13. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fi brosis score: a noninvasive system that identifi es liver fi brosis in patients with NAFLD. Hepatology 2007; 45(4):846–854. doi:10.1002/hep.21496

14. Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and NAFLD fi brosis score improves the noninvasive diagnostic accuracy for severe liver fi brosis in patients with nonalcoholic fatty liver disease. Liver Int 2015; 35(5):1566–1573.doi:10.1111/liv.12584